Author: "Jean-Michel Dorey" / Topic: business.industry - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Jean-Michel Dorey"' showing total 30 results

Start Over Author "Jean-Michel Dorey" Topic business.industry

30 results on '"Jean-Michel Dorey"'

1. Comparative diagnosis interest of NfL and pNfH in CSF and plasma in a context of FTD–ALS spectrum

Author: Mathieu Herrmann, Maïté Formaglio, Hélène Mollion, Jean-Michel Dorey, Muriel Bost, Jean Escal, Isabelle Quadrio, Emilien Bernard, Anthony Fourier, Luc Zimmer, and Elisabeth Ollagnon-Roman
Subjects: Oncology, medicine.medical_specialty, Neurology, business.industry, Context (language use), Frontotemporal lobar degeneration, medicine.disease, Cerebrospinal fluid, Internal medicine, Cohort, medicine, Neurology (clinical), Differential diagnosis, Amyotrophic lateral sclerosis, business, Frontotemporal dementia
Abstract: The ‘Frontotemporal dementia–Amyotrophic lateral sclerosis Spectrum’ (FAS) encompasses different phenotypes, including cognitive disorders (frontotemporal dementia, FTD) and/or motor impairments (amyotrophic lateral sclerosis, ALS). The aim of this study was to apprehend the specific uses of neurofilaments light chain (NfL) and phosphorylated neurofilaments heavy chain (pNfH) in a context of FAS. First, NfL and pNfH were measured in 39 paired cerebrospinal fluid (CSF) and plasma samples of FAS and primary psychiatric disorders (PPD) patients, considered as controls. Secondly, additional plasma samples were included to examine a larger cohort of 81 samples composed of symptomatic FAS and PPD patients, presymptomatic and non-carrier relatives individuals. The measures were performed using Simoa technology. There was a positive correlation between CSF and plasma values for NfL (p
Published: 2021

2. Redefining peripheral inflammation signature in schizophrenia based on the real-world FACE-SZ cohort

Author: Christophe Lançon, Baptiste Pignon, T Korchia, Guillaume Fond, Damien Etchecopar-Etchart, Raphaëlle Richieri, Christine Passerieux, Jasmina Mallet, David Misdrahi, Delphine Capdevielle, Mélanie Faugere, Mathieu Urbach, F. Schürhoff, N Coulon, Bruno Aouizerate, Romain Rey, Ophélia Godin, L. Boyer, Julien Dubreucq, P.L. Sunhary de Verville, Isabelle Chereau, Jean-Michel Dorey, Marion Leboyer, Julie Clauss-Kobayashi, Caroline Dubertret, Fabrice Berna, P.-M. Llorca, Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Fondation FondaMental [Créteil], Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Henri Mondor, Neuropsychologie Cognitive et Physiopathologie de la Schizophrénie (NCPS), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Civil de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Les Hôpitaux Universitaires de Strasbourg (HUS), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre hospitalier Charles Perrens [Bordeaux], Nutrition et Neurobiologie intégrée (NutriNeuro), Université de Bordeaux (UB)-Institut Polytechnique de Bordeaux-Ecole nationale supérieure de chimie, biologie et physique-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut Pascal (IP), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne), Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA), Centre Référent de Réhabilitation Psychosociale [CH Alpes Isère], Centre Hospitalier Alpes Isère, Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier le Vinatier [Bron], Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de Neurosciences cognitives et intégratives d'Aquitaine (INCIA), Université Bordeaux Segalen - Bordeaux 2-Université Sciences et Technologies - Bordeaux 1 (UB)-SFR Bordeaux Neurosciences-Centre National de la Recherche Scientifique (CNRS), Laboratoire de recherches cliniques et en santé publique sur les handicaps psychique, cognitif et moteur (HANDIReSP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Centre Hospitalier de Versailles André Mignot (CHV), FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group: P M Llorca, C Lançon, L Boyer, Imagerie MOléculaire pour applications THéranostiques personnalisées (IMOTHEP), Institut FRESNEL (FRESNEL), Centre National de la Recherche Scientifique (CNRS)-École Centrale de Marseille (ECM)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)-École Centrale de Marseille (ECM)-Aix Marseille Université (AMU)- Hôpital de la Timone [CHU - APHM] (TIMONE), Institut de Génomique Fonctionnelle (IGF), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Université Bordeaux Segalen - Bordeaux 2-Université Sciences et Technologies - Bordeaux 1-SFR Bordeaux Neurosciences-Centre National de la Recherche Scientifique (CNRS)
Subjects: Adult, Male, Quality of life, medicine.medical_specialty, Inflammation, Overweight, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Medicine, Humans, ComputingMilieux_MISCELLANEOUS, Biological Psychiatry, Pharmacology, Psychiatry, business.industry, Patient Acuity, medicine.disease, Physical activity level, 3. Good health, 030227 psychiatry, Peripheral, C-Reactive Protein, Schizophrenia, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Cohort, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Female, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], medicine.symptom, business, Inflammatory biomarker, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Biomarkers
Abstract: International audience; Background: Peripheral inflammation is associated with impaired prognosis in schizophrenia (SZ). Highly sensitive C-reactive protein (hs-CRP) is the most used inflammatory biomarker in daily practice. However, no consensual cut-off has been determined to date to discriminate patients with peripheral inflammation from those without.Aims: To determine if patients with peripheral inflammation between 1 and 3 mg/L had poorer outcomes compared to those with undetectable CRP ( 1 mg/L is a reliable marker to detect peripheral inflammation in patients with schizophrenia.
Published: 2021

3. [Paradoxical reactions to benzodiazepines in the elderly]

Author: Alexis Lepetit, Jean-Michel Dorey, Christine Champion, Teddy Novais, and Pierre Krolak-Salmon
Subjects: medicine.medical_specialty, education.field_of_study, business.industry, Population, Paradoxical reaction, Cognition, Semiology, Aggression, Benzodiazepines, Neuropsychology and Physiological Psychology, Elderly population, Medicine, Humans, Neurology (clinical), Geriatrics and Gerontology, business, Psychiatry, education, Very high risk, Neurocognitive, Biological Psychiatry, Aged
Abstract: The prevalence of paradoxical reactions to benzodiazepines is estimated to be approximately 1% in the general population. The semiology can be very varied, diverse and misleading. Advanced age as well as cognitive disorders are classically described in the literature as risk factors for developing paradoxical reactions. However, this literature review only identified a limited number of articles focusing on the elderly and only one article on patients with neurocognitive disorders. This paradoxical situation raises questions as to whether these are unpublished clinical observations or whether the elderly population is really at risk, especially patients with neurocognitive disorders. Semiology can be confused with underlying neurocognitive disorders. Paradoxical reactions are ultimately only rarely or not evoked, leading to a very high risk of iatrogeny. It is therefore important to be aware of these paradoxical effects in order to be able to evoke them rapidly. The most striking semiological element would be the suddenness of onset of self-aggressive or hetero-aggressive behaviours.
Published: 2021

4. Impact of Cognitive, Functional, Behavioral Disorders, and Caregiver Burden on the Risk of Nursing Home Placement

Author: Marine Dufournet, Virginie Dauphinot, Claire Moutet, Mathieu Verdurand, Floriane Delphin-Combe, Pierre Krolak-Salmon, Florian Delphin-Combe, Zaza Makaroff, Denis Federico, Marie-Hélène Coste, Isabelle Rouch, Jean-Michel Dorey, Alexis Lepetit, Keren Danaila, Julien Vernaudon, Anthony Bathsavanis, Alain Sarciron, Yves Guilhermet, Sylvain Gaujard, Pierre Grosmaître, Centre Mémoire de Ressources et de Recherche Lyon (CMRR), Hospices Civils de Lyon (HCL)-Hôpital des Charpennes [CHU - HCL], Hospices Civils de Lyon (HCL), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Mémoire de Ressources et de Recherche [Lyon] (CMRR), MEMORA group: Pierre Krolak-Salmon, Virginie Dauphinot, Florian Delphin-Combe, Zaza Makaroff, Denis Federico, Marie-Hélène Coste, Isabelle Rouch, Jean-Michel Dorey, Alexis Lepetit, Keren Danaila, Julien Vernaudon, Anthony Bathsavanis, Alain Sarciron, Yves Guilhermet, Sylvain Gaujard, Pierre Grosmaître, Claire Moutet, Mathieu Verdurand, CCSD, Accord Elsevier, Centre de recherche en neurosciences de Lyon (CRNL), and Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Male, medicine.medical_specialty, Longitudinal study, Activities of daily living, [SDV]Life Sciences [q-bio], Psychological intervention, neurocognitive disorders, functional limitations, Risk Assessment, Nursing home placement, 03 medical and health sciences, Patient Admission, 0302 clinical medicine, Cost of Illness, medicine, Humans, Dementia, Cognitive Dysfunction, Apathy, Longitudinal Studies, 030212 general & internal medicine, Psychiatry, General Nursing, Aged, Aged, 80 and over, caregiver burden, business.industry, Health Policy, General Medicine, Caregiver burden, medicine.disease, Nursing Homes, 3. Good health, [SDV] Life Sciences [q-bio], Caregivers, Attention Deficit and Disruptive Behavior Disorders, Attributable risk, Anxiety, Female, neuropsychiatric symptoms, France, Geriatrics and Gerontology, medicine.symptom, business, 030217 neurology & neurosurgery, dementia
Abstract: Objectives To estimate the attributable fraction of nursing home placement associated with cognitive impairment, neuropsychiatric symptoms, behavioral disorders, functional limitations, and caregiver burden. Design Longitudinal study conducted on the “MEMORA cohort” linked with both regional public health insurance and hospital discharge databases. Setting Memory center at the University Hospital of Lyon, France. Participants A sample of 2456 outpatients attending the memory center between 2012 and 2017. Measures Cognitive impairment, functional limitations, neuropsychiatric symptoms/behavioral disorders, and caregiver burden were measured with the Mini-Mental State Examination, the Instrumental Activities of Daily Living scale, the Neuropsychiatric Inventory (NPI), and a short version of the Zarit Burden Inventory, respectively. Sociodemographics characteristics were collected during the first visit. Comorbidities were gathered from the hospital discharge database. Dates of nursing home placement were obtained from the public health insurance database. Results More than 38% of nursing home placements were attributable to caregiver burden, and the attributable fraction associated with functional limitations exceeded 35%. Between 20% and 25% of nursing home placements were due to cognitive impairment whereas less than 16% were attributable to neuropsychiatric symptoms or behavioral disorders. The associations between anxiety or agitation and nursing home placement were mediated by caregiver burden. Apathy or aberrant motor behaviors were associated with a higher risk of nursing home placement independently of caregiver burden. Conclusions/Implications Our findings suggest that a high proportion of nursing home placements are attributable to caregiver burden and functional limitations in outpatients attending a memory center. Cognitive impairment and neuropsychiatric symptoms or behavioral disorders contribute less to nursing home placements. Interventions directed to delay nursing home placement should emphasize actions toward reducing caregiver burden and functional limitations of patients.
Published: 2019

5. Le syndrome sérotoninergique : une revue actualisée de la littérature

Author: T. d’Amato, M. Nourredine, Benjamin Rolland, Jean-Michel Dorey, Bruno Mégarbane, and L. Jurek
Subjects: medicine.medical_specialty, business.industry, Gastroenterology, Cognition, Therapeutic education, Serotonergic, 030226 pharmacology & pharmacy, Serotonin syndrome, 03 medical and health sciences, 0302 clinical medicine, Clinical heterogeneity, Internal Medicine, medicine, Drug adverse effect, medicine.symptom, business, Intensive care medicine, 030217 neurology & neurosurgery, Pharmacogenetics
Abstract: The serotonin syndrome is a potentially deadly complication resulting from drug adverse effect, drug-drug interaction or overdose involving one or more serotonergic molecules, e.g., antidepressants, psychostimulants and sometimes an "ignored" serotonergic compound. The serotonin syndrome typically consists of a clinical triad including cognitive/behavioral, neurovegetative and neuromuscular features. However, this syndrome is characterized by major clinical heterogeneity, making the diagnosis difficult in practice. Moreover, many practitioners are quite unaware of this syndrome. Available scores and classifications can help physicians in their diagnosis approach. Knowing the responsible molecules, their potential interactions and mechanisms of action can help preventing this complication allowing therapeutic education among patients. This updated article reviews the clinical presentation, prevention, management, and pathophysiology of the serotonin syndrome, and addresses the most recent advances in pharmacogenetics regarding this syndrome.
Published: 2019

6. Validation and refinement of the clinical staging model in a French cohort of outpatient with schizophrenia (FACE-SZ)

Author: Ophelia Godin, Guillaume Fond, Ewa Bulzacka, Frank Schürhoff, Laurent Boyer, Andre Myrtille, Meja Andrianarisoa, Bruno Aouizerate, Fabrice Berna, Delphine Capdevielle, Isabelle Chereau, Jean-Michel Dorey, Caroline Dubertret, Julien Dubreucq, Catherine Faget, Christophe Lancon, Sylvain Leignier, Jasmina Mallet, David Misdrahi, Christine Passerieux, Romain Rey, Paul Roux, Pierre Vidailhet, Dominique Costagliola, Marion Leboyer, Pierre-Michel Llorca, Méja Andrianarisoa, Olivier Blanc, Lore Brunel, Isabelle Chéreau-Boudet, Gabrielle Chesnoy-Servanin, Jean-Marie Danion, Thierry D'Amato, Arnaud Deloge, Claire Delorme, Hélène Denizot, Cécile Fluttaz, Sandrine Fonteneau, Franck Gabayet, Elisabeth Giraud-Baro, Marie-Christine Hardy-Baylé, Delphine Lacelle, Christophe Lançon, Hakim Laouamri, Tifenn Le Gloahec, Yann Le Strat, Emeline Metairie, Pauline Peri, Sylvie Pires, Céline Portalier, Céline Roman, Mathilde Sebilleau, Aurélie Schandrin, Priscille Schneider, Franck Schurhoff, Arnaud Tessier, Anne-Marie Tronche, Mathieu Urbach, Florence Vaillant, Aurélie Vehier, Estelle Vilà, Hanan Yazbek, Anna Zinetti-Bertschy, CCSD, Accord Elsevier, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Fondation FondaMental [Créteil], Sorbonne Université (SU), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), IMRB - 'Neuropsychiatrie translationnelle' [Créteil] (U955 Inserm - UPEC), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Hôpital de la Colombière, Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre hospitalier Charles Perrens [Bordeaux], Nutrition et Neurobiologie intégrée (NutriNeuro), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Recherche Agronomique (INRA)-Université Sciences et Technologies - Bordeaux 1 (UB)-Institut Polytechnique de Bordeaux-Ecole nationale supérieure de chimie, biologie et physique, Neuropsychologie Cognitive et Physiopathologie de la Schizophrénie (NCPS), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Civil de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), CHU Clermont-Ferrand, Université d'Auvergne - Clermont-Ferrand I (UdA), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Référent de Réhabilitation Psychosociale [CH Alpes Isère], Centre Hospitalier Alpes Isère, Assistance Publique - Hôpitaux de Marseille (APHM), Institut de Neurosciences cognitives et intégratives d'Aquitaine (INCIA), Université Bordeaux Segalen - Bordeaux 2-Université Sciences et Technologies - Bordeaux 1 (UB)-SFR Bordeaux Neurosciences-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier de Versailles André Mignot (CHV), Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group: Méja Andrianarisoa 16 , Bruno Aouizerate 17 , Fabrice Berna 18 , Olivier Blanc 19 , Lore Brunel 16 , Ewa Bulzacka 16 , Delphine Capdevielle 20 , Isabelle Chéreau-Boudet 19 , Gabrielle Chesnoy-Servanin 21 , Jean-Marie Danion 18 , Thierry D'Amato 21 , Arnaud Deloge 22 , Claire Delorme 23 , Hélène Denizot 19 , Jean-Michel Dorey 21 , Caroline Dubertret 24 , Julien Dubreucq 23 , Catherine Faget 25 , Cécile Fluttaz 23 , Guillaume Fond 16 , Sandrine Fonteneau 26 , Franck Gabayet 23 , Elisabeth Giraud-Baro 23 , Marie-Christine Hardy-Baylé 26 , Delphine Lacelle 19 , Christophe Lançon 25 , Hakim Laouamri 27 , Marion Leboyer 16 , Tifenn Le Gloahec 16 , Yann Le Strat 24 , Pierre-Michel Llorca 19 , Jasmina Mallet 28 , Emeline Metairie 25 , David Misdrahi 22 , Christine Passerieux 26 , Pauline Peri 25 , Sylvie Pires 19 , Céline Portalier 24 , Romain Rey 21 , Céline Roman 23 , Mathilde Sebilleau 26 , Aurélie Schandrin 20 , Priscille Schneider 18 , Franck Schurhoff 16 , Arnaud Tessier 22 , Anne-Marie Tronche 19 , Mathieu Urbach 26 , Florence Vaillant 25 , Aurélie Vehier 21 , Pierre Vidailhet 18 , Estelle Vilà 22 , Hanan Yazbek 20 , Anna Zinetti-Bertschy 18, Centre de Psychiatrie et Neurosciences (U894), Université Montpellier 1 - UFR de Médecine (UM1 Médecine), Université Montpellier 1 (UM1), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes (UGA), Laboratoire de sciences cognitives et psycholinguistique (LSCP), Département d'Etudes Cognitives - ENS Paris (DEC), École normale supérieure - Paris (ENS Paris)-École normale supérieure - Paris (ENS Paris)-École des hautes études en sciences sociales (EHESS)-Centre National de la Recherche Scientifique (CNRS), Hôpital Charles Perrens, Centres d'addictologies - Région Centre, Physiopathologie clinique et expérimentale de la schizophrénie, Université Louis Pasteur - Strasbourg I-IFR37-Institut National de la Santé et de la Recherche Médicale (INSERM), Vulnérabilité à la schizophrénie : des bases neurobiologiques à la thérapeutique, Centre Hospitalier le Vinatier [Bron]-IFR19-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Université Bordeaux Segalen - Bordeaux 2-Université Sciences et Technologies - Bordeaux 1-SFR Bordeaux Neurosciences-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier de Bayeux, Psychiatrie, Centre Hospitalier le Vinatier [Bron], Centre Hospitalier de Saint-Egrève (CH Ste-Egrève), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Département des maladies infectieuses, Institut de Veille Sanitaire (INVS), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), Laboratoire de neuropsychologie cognitive et prise en charge des troubles de la communication schizophrénique, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Hôpital Mignot, Université Paris Diderot - Paris 7 (UPD7), Service de pédiatrie multidisciplinaire [Hôpital de la Timone Enfants - APHM], Hôpital de la Timone [CHU - APHM] (TIMONE), Neuropsychiatrie : recherche épidémiologique et clinique, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Université Panthéon-Sorbonne - UFR Histoire (UP1 UFR09), Université Panthéon-Sorbonne (UP1), Centre de recherche en neurosciences de Lyon (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Neuropsychologie Cognitive et Physiopathologie de la Schizophrénie, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA)-Hôpital Civil de Strasbourg, Dynamique des capacités humaines et des conduites de santé (EPSYLON), Université Montpellier 1 (UM1)-Université Paul-Valéry - Montpellier 3 (UM3)-Université de Montpellier (UM), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Bordeaux (UB)-Institut Polytechnique de Bordeaux-Ecole nationale supérieure de chimie, biologie et physique-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Civil de Strasbourg-Université de Strasbourg (UNISTRA)
Subjects: Adult, Male, Pediatrics, medicine.medical_specialty, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.NEU.PC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, Comorbidity, Neuropsychological Tests, Medication Adherence, Machine Learning, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Cognition, Outpatients, medicine, Humans, Cognitive Dysfunction, Stage (cooking), Medical prescription, Major depressive episode, Biological Psychiatry, Pharmacology, Depressive Disorder, Major, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, [SCCO.NEUR] Cognitive science/Neuroscience, Neuropsychology, [SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, medicine.disease, Prognosis, 030227 psychiatry, 3. Good health, Mood, Clinical staging, Schizophrenia, Cognitive remediation therapy, Cohort, Polypharmacy, Female, Schizophrenic Psychology, France, medicine.symptom, business, [SDV.NEU.SC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Algorithms
Abstract: International audience; Objective: Existing staging models have not been fully validated. Thus, after classifying patients with schizophrenia according to the staging model proposed by McGorry et al. (2010), we explored the validity of this staging model and its stability after one-year of follow-up.Method: Using unsupervised machine-learning algorithm, we classified 770 outpatients into 5 clinical stages, the highest being the most severe. Analyses of (co)variance were performed to compare each stage in regard to socio-demographics factors, clinical characteristics, co-morbidities, ongoing treatment and neuropsychological profiles.Results: The precision of clinical staging can be improved by sub-dividing intermediate stages (II and III). Clinical validators of class IV include the presence of concomitant major depressive episode (42.6% in stage IV versus 3.4% in stage IIa), more severe cognitive profile, lower adherence to medication and prescription of >3 psychotropic medications. Follow-up at one-year showed good stability of each stage.Conclusion: Clinical staging in schizophrenia could be improved by adding clinical elements such as mood symptoms and cognition to severity, relapses and global functioning. In terms of therapeutic strategies, attention needs to be paid on the factors associated with the more stages of schizophrenia such as treatment of comorbid depression, reduction of the number of concomitant psychotropic medications, improvement of treatment adherence, and prescription of cognitive remediation.
Published: 2018

7. How do patients with Alzheimer's disease imagine their pain?

Author: Bernard Laurent, Jean-Claude Getenet, Julien Labouré, Céline Borg, Emilie Sala, Isabelle Rouch, Jean-Michel Dorey, Hanna Chainay, Chainay, Hanna, Laboratoire d'Etude des Mécanismes Cognitifs (EMC), and Université Lumière - Lyon 2 (UL2)
Subjects: Pain Threshold, medicine.medical_specialty, media_common.quotation_subject, Pain tolerance, Population, Pain, Disease, 03 medical and health sciences, [SCCO]Cognitive science, 0302 clinical medicine, Alzheimer Disease, medicine, Humans, Cognitive Dysfunction, 030212 general & internal medicine, education, ComputingMilieux_MISCELLANEOUS, media_common, Pain Measurement, education.field_of_study, business.industry, Cognition, Pain scale, [SCCO] Cognitive science, Pain management, Response bias, Anesthesiology and Pain Medicine, Feeling, Physical therapy, business, 030217 neurology & neurosurgery
Abstract: INTRODUCTION Pain is underdiagnosed and undertreated in patients with Alzheimer's disease (AD). Pain management is of major importance in this population to limit behavioural and functional consequences. Our study aimed to assess the capacity of AD patients to represent pain using a questionnaire exploring daily painful situations and to determine the most appropriate pain scale assessment. METHODS Twenty-eight patients with mild AD, 21 with moderate AD and 28 matched controls underwent the Situation Pain Questionnaire (SP-Q) and assessed imaginary pain with four pain scales. Two scores were compared between the three groups: the P(A) discrimination score and the response bias β score. P(A) reflects the degree of discrimination between high-pain and low-pain events, whereas the β score means the degree to which situations are considered as painful. RESULTS Our results showed that AD patients hardly discriminated the high- from low-pain events. Compared to controls, the mean P(A) score was significantly lower for Mild AD (p
Published: 2020

8. Overexpression of complement component C4 in the dorsolateral prefrontal cortex, parietal cortex, superior temporal gyrus and associative striatum of patients with schizophrenia

Author: Anne-Lise Bohec, Marie-Françoise Suaud-Chagny, Jean-Michel Dorey, Thierry d'Amato, Ryad Tamouza, Romain Rey, Marion Leboyer, Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Lyon, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), IMRB - 'Neuropsychiatrie translationnelle' [Créteil] (U955 Inserm - UPEC), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CCSD, Accord Elsevier, Centre de recherche en neurosciences de Lyon (CRNL), and Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: 0301 basic medicine, Adolescent, Synaptic pruning, [SDV]Life Sciences [q-bio], Immunology, Posterior parietal cortex, Prefrontal Cortex, 03 medical and health sciences, Behavioral Neuroscience, Superior temporal gyrus, 0302 clinical medicine, Parietal Lobe, Neuroplasticity, medicine, Humans, Temporal cortex, Complement component 4, Endocrine and Autonomic Systems, business.industry, Complement C4, Temporal Lobe, Dorsolateral prefrontal cortex, [SDV] Life Sciences [q-bio], 030104 developmental biology, medicine.anatomical_structure, Cerebral cortex, Schizophrenia, business, Neuroscience, 030217 neurology & neurosurgery
Abstract: Background In schizophrenia, abnormal synaptic pruning during adolescence may be due to altered expression of the Complement component 4 (C4). Overexpression of C4 genes has been identified in the total cerebral cortex and in 6 different brain regions of schizophrenic patients compared to controls. These alterations should be replicated and extended to other brain regions relevant to schizophrenia. Moreover, it remains unknown whether cerebral and peripheral C4 expression levels are related. Methods We explored C4 genes expression both at the cerebral and peripheral levels. Using shinyGEO application we analyzed C4 expression from eight Gene Expression Omnibus datasets obtained from 196 schizophrenic patients and 182 control subjects. First, we compared C4 expression between schizophrenic patients and controls in postmortem cerebral samples from 7 different brain regions. Then, we compared C4 expression between schizophrenic patients and controls in 4 peripheral tissues. Results At the cerebral level, we provide further evidence of C4 overexpression in schizophrenic patients. Consistently with a previous report, we found C4 overexpression in the dorsolateral prefrontal cortex and in the parietal cortex of schizophrenic patients. The observation of C4 overexpression was further extended to the superior temporal cortex and the associative striatum of schizophrenic patients. Conversely, no significant alteration of C4 expression was observed in peripheral tissues. Conclusions Our results support the hypothesis of an excessive Complement activity in various brain regions of schizophrenic patients which may disrupt the synaptic pruning process occurring during adolescence. C4 overexpression may be specific to the cerebral tissue while other alterations of the Complement system may be detected at the systemic level.
Published: 2020

9. Impact of vascular risk factors on clinical outcome in elderly patients with depression receiving electroconvulsive therapy

Author: Jerome Brunelin, Filipe Galvao, Lucie Jurek, Mikail Nourredine, Jean-Michel Dorey, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Centre Hospitalier le Vinatier [Bron], Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CCSD, Accord Elsevier, Centre de recherche en neurosciences de Lyon (CRNL), and Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: medicine.medical_specialty, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Population, behavioral disciplines and activities, Late-life depression, 03 medical and health sciences, 0302 clinical medicine, Electroconvulsive therapy, Elderly, Rating scale, Risk Factors, Internal medicine, mental disorders, Medicine, Humans, Apathy, education, Electroconvulsive Therapy, Depression (differential diagnoses), Aged, Retrospective Studies, Psychiatric Status Rating Scales, education.field_of_study, Framingham Risk Score, business.industry, Depression, Beck Depression Inventory, ECT, Vascular risk-factor, Late life depression, 3. Good health, 030227 psychiatry, [SDV] Life Sciences [q-bio], Psychiatry and Mental health, Clinical Psychology, Treatment Outcome, medicine.symptom, business, 030217 neurology & neurosurgery
Abstract: Background Although electroconvulsive therapy (ECT) is a highly effective, safe, and well-tolerated antidepressant treatment for late-life depression (LLD), there is large variability in response rates across individuals. We hypothesized that these variations would be in part explained by the level of vascular risk in this population. We therefore compared response rates to ECT in patients with LLD presenting with or without vascular risk factors (VRF). Methods 52 patients with LLD (age > 55) who received a course of ECT were separated into 2 groups according to the presence of VRF (n = 20) or not (n = 32). Framingham score (10-year risk for developing a coronary heart disease) was calculated for each patient. Our primary outcome was the number of responders to ECT in each group (defined as at least 50% decrease of the Montgomery–Asberg Depression Rating Scale score following ECT course). Scores at the self-rated Beck Depression Inventory are also reported. Results Patients with VRF presented significant lower response rates to ECT (12 out of 20; 60%) than patients without VRF (30 out of 32; 94%; p = 0.004). A negative correlation was found between Framingham score and changes in depression scores pre/post ECT (r = -0.42; p = 0.0039). Limitations Our study was limited by sample size and retrospective design. Conclusion Patients with LLD and VRF showed lower response rates to ECT than those without VRF. The more the VRF increased, the less the antidepressant effect of ECT was observed. Results are discussed in light of the role of apathy in clinical response to ECT.
Published: 2020

10. Brain Volume Predicts Behavioral and Psychological Symptoms in Alzheimer’s Disease

Author: Isabelle Rouch, Catherine Padovan, Romain Bouet, Olivier Moreaud, Philippe Robert, Zaza Makaroff, Jean-Michel Dorey, Denis Federico, Nawele Boublay, Alzheimer’s Disease Neuroimaging Initiative, Marie-Odile Barrellon, Pierre Krolak-Salmon, Isabelle Gallice, Laboratoire de Psychologie et NeuroCognition (LPNC ), Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), and Centre Hospitalier Universitaire [Grenoble] (CHU)
Subjects: 0301 basic medicine, Male, medicine.medical_specialty, Orbital gyri, Behavioral Symptoms, Neuropsychological Tests, Cohort Studies, 03 medical and health sciences, [SCCO]Cognitive science, 0302 clinical medicine, Physical medicine and rehabilitation, Neuroimaging, Alzheimer Disease, Predictive Value of Tests, medicine, Dementia, Humans, Cognitive Dysfunction, Longitudinal Studies, Prospective Studies, Prospective cohort study, Anterior cingulate cortex, ComputingMilieux_MISCELLANEOUS, Aged, Aged, 80 and over, business.industry, General Neuroscience, Brain, Cognition, General Medicine, medicine.disease, Mental Status and Dementia Tests, Magnetic Resonance Imaging, Frontal Lobe, Psychiatry and Mental health, Clinical Psychology, 030104 developmental biology, medicine.anatomical_structure, Frontal lobe, Brain size, Disease Progression, Female, Geriatrics and Gerontology, business, 030217 neurology & neurosurgery
Abstract: Background Behavioral and psychological symptoms of dementia (BPSD) are frequent and troublesome for patients and caregivers. Considering possible preventive approaches, a better understanding of underlying neural correlates of BPSD is crucial. Objective The aim is to assess whether brain regional volume predicts behavioral changes in mild AD. Methods This work took part from the PACO study, a multicenter and prospective study that included 252 patients with mild AD from 2009 to 2014. Fifty-three patients were retained. Forty healthy matched control subjects from the ADNI cohort were included as controls. Voxel-based morphometry analysis was conducted to assess regional brain volume using baseline MRI scans as a predictor of future behavioral changes over a period of 18 months. Behavior was assessed at baseline and longitudinally at 6-month intervals using the shortened form of the Neuropsychiatric Inventory (NPI). Results The volume of 23 brain structures in frontal, temporal, parietal, occipital, subcortical regions and cerebellum predicted the evolution of NPI scores. Frontal volume was the most powerful predictor with frontal gyri, anterior cingulate cortex, and orbital gyri being particularly involved. Conclusion To our knowledge, this is the first study assessing regional brain volumes as predictors of behavioral changes considered at earlier stages of AD. Up to 23 brain structures were associated with an increased risk of developing BPSD. Frontal lobe volume was the strongest predictor of future evolution of NPI. The involvement of multiple structures in the prediction of behavior suggests a role of the main large-scale networks involved in cognition.
Published: 2020

11. Early and very early‐onset schizophrenia compared with adult‐onset schizophrenia: French FACE‐SZ database

Author: Romain Rey, Ophélia Godin, Pierre Vidailhet, Jasmina Mallet, Hélène Denizot, Christophe Lançon, Myrtille André, Isabelle Chereau, E. Bulzacka, Paul Roux, Marion Leboyer, Lore Brunel, Catherine Faget, N Coulon, David Misdrahi, George M. Anderson, Sylvain Leignier, Franck Schürhoff, Guillaume Fond, Fabrice Berna, Caroline Dubertret, Jean-Michel Dorey, Delphine Capdevielle, Christine Passerieux, Bruno Aouizerate, Julien Dubreucq, M. Andrianarisoa, Molecular virology and immunology – Physiopathology and therapeutic of chronic viral hepatitis (Team 18) (Inserm U955), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université Pierre et Marie Curie - Paris 6 (UPMC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Fondation FondaMental [Créteil], Aix Marseille Université (AMU), Assistance Publique - Hôpitaux de Marseille (APHM), CRC Scotland & London, Service de psychiatrie, CHU Clermont-Ferrand, Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Pôle de psychiatrie, Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud )-CHU Marseille, Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Laboratoire de sciences cognitives et psycholinguistique (LSCP), Département d'Etudes Cognitives - ENS Paris (DEC), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École des hautes études en sciences sociales (EHESS)-Centre National de la Recherche Scientifique (CNRS), Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes (UGA), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance Publique-Hôpitaux de Marseille (AP-HM), Centre de recherche en neurosciences de Lyon (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), École normale supérieure - Paris (ENS Paris), and Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS Paris)
Subjects: Adult, Male, Pediatrics, medicine.medical_specialty, Databases, Factual, Untreated psychosis, 050105 experimental psychology, early‐onset schizophrenia, lcsh:RC321-571, 03 medical and health sciences, Behavioral Neuroscience, 0302 clinical medicine, very early‐onset schizophrenia, medicine, Humans, 0501 psychology and cognitive sciences, In patient, Age of Onset, Child, lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry, Original Research, Psychiatric Status Rating Scales, Early onset schizophrenia, business.industry, 05 social sciences, Neuropsychology, medicine.disease, Prognosis, Very early onset, 3. Good health, Psychotic Disorders, Schizophrenia, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, symptomatology, dup, Female, Schizophrenic Psychology, France, business, duration of untreated psychosis, 030217 neurology & neurosurgery, adult‐onset schizophrenia
Abstract: Objective To compare the clinical symptomatology in patients with Early‐Onset Schizophrenia (EOS, N = 176), especially the subgroup Very Early Onset Schizophrenia (VEOS) and Adult Onset Schizophrenia (AOS, N = 551). Method In a large French multicentric sample, 727 stable schizophrenia patients, classified by age at onset of the disorder, were assessed using standardized and extensive clinical and neuropsychological batteries: AOS with onset ≥ 18 years and EOS with onset, To describe schizophrenia from childhood to adulthood is complex and patients with early‐onset schizophrenia (EOS) remain undiagnosed or misclassified, especially the subgroup with very early‐onset schizophrenia (VEOS). In patients with VEOS, the DUP which exceeds 8 years, almost eight times higher than in patients with AOS, objective the problem of early diagnosis and the need to develop diagnostic programs and management cares.
Published: 2020

12. Clinical guidelines for the management of depression with specific comorbid psychiatric conditions French recommendations from experts (the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental)

Author: C. Rabu, Wissam El-Hage, Isabel Nieto, Emmanuel Haffen, Antoine Yrondi, P. Courtet, Marion Leboyer, Franck Bellivier, Najib Allaïli, Guillaume Vaiva, Fanny Moliere, Jean-Michel Dorey, J.-B. Genty, Frédéric Haesebaert, Sylvie Lancrenon, Olivier Doumy, Djamila Bennabi, Laurent Schmitt, Florian Stephan, Bruno Aouizerate, Thierry Bougerol, C. Lançon, S. Destouches, Michel Walter, Raphaëlle Richieri, Thomas Charpeaud, J. Holtzmann, Pierre-Michel Llorca, M. Lefebvre, Vincent Camus, Centre d'expertise de la performance Gilles Cometti [Dijon] (CEP), Université de Bourgogne (UB), Sylia Stat Lancrenon S.A.S., Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7), Fondation FondaMental [Créteil], Clinique Psychiatrique Universitaire, Departement de Psychiatrie, Hôpital de la Conception [CHU - APHM] (LA CONCEPTION ), Deutsches Elektronen-Synchrotron [Zeuthen] (DESY), Helmholtz-Gemeinschaft, Laboratoire de Neurosciences Fonctionnelles et Pathologies (LNFP), Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Laboratoire de Neurosciences Intégratives et Cliniques - UFC (EA 481) (NEURO), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université de Franche-Comté (UFC), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Groupe d'étude des proliférations lymphoïdes (GPL), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), ERL 6230, Centre National de la Recherche Scientifique (CNRS), Helmholtz-Gemeinschaft = Helmholtz Association, Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), and Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Subjects: Male, Psychopharmacology, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Comorbidity, Scientific evidence, 0302 clinical medicine, Elderly, lcsh:Psychiatry, 030212 general & internal medicine, Depression (differential diagnoses), ComputingMilieux_MISCELLANEOUS, Psychiatry, Anxiety disorders, Major depressive disorder, Pharmacotherapy, Substance use disorders, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, 3. Good health, Neuropsychopharmacology, Psychiatry and Mental health, Practice Guidelines as Topic, Female, France, Biological psychiatry, Management of depression, Foundations, Research Article, medicine.medical_specialty, Substance-Related Disorders, lcsh:RC435-571, Personality Disorders, 03 medical and health sciences, medicine, Humans, Association (psychology), Expert Testimony, Biological Psychiatry, Aged, Depressive Disorder, Major, business.industry, [SCCO.NEUR]Cognitive science/Neuroscience, medicine.disease, Personality disorders, 030227 psychiatry, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Substance use, business
Abstract: International audience; Background Recommendations for pharmacological treatments of major depression with specific comorbid psychiatric conditions are lacking. Method The French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental developed expert consensus guidelines for the management of depression based on the RAND/UCLA Appropriatneness Method. Recommendations for lines of treatment are provided by the scientific committee after data analysis and interpretation of the results of a survey of 36 psychiatrist experts in the field of major depression and its treatments. Results The expert guidelines combine scientific evidence and expert clinician's opinion to produce recommendations for major depression with comorbid anxiety disorders, personality disorders or substance use disorders and in geriatric depression. Conclusion These guidelines provide direction addressing common clinical dilemmas that arise in the pharmacologic treatment of major depression with comorbid psychiatric conditions.
Published: 2019

13. One-Year Evolution of Behavioral and Psychological Symptoms of Dementia in Patients Initially Hospitalized in Cognitive Behavioral Units: The EVITAL Prospective Cohort

Author: Florence Fabre, Magalie Freulon, Isabelle Rouch, Nicolas Auguste, Christelle Mouchoux, Pierre Krolak-Salmon, Bernard Laurent, Sophie Jacqueline, Géraldine Martin-Gaujard, Elodie Pongan, Claire Sellier, Jean-Michel Dorey, Béatrice Trombert, and Denis Federico
Subjects: Male, medicine.medical_specialty, Psychosis, Longitudinal study, Clinical Dementia Rating, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, mental disorders, Humans, Medicine, Dementia, Longitudinal Studies, Prospective Studies, 030212 general & internal medicine, Prospective cohort study, Psychiatry, Aged, 80 and over, Psychotropic Drugs, business.industry, General Neuroscience, General Medicine, Mental Status and Dementia Tests, medicine.disease, Hospitalization, Psychiatry and Mental health, Clinical Psychology, Mood, Test score, Cohort, Disease Progression, Linear Models, Female, Geriatrics and Gerontology, Factor Analysis, Statistical, business, 030217 neurology & neurosurgery, Follow-Up Studies
Abstract: BACKGROUND The 2008-2012 French Alzheimer's Plan has provided hospital Cognitive and Behavioral Units (CBU) to improve the management of patients with productive behavioral and psychological symptoms of dementia (BPSD). Little is known concerning the behavioral outcome of these patients after discharge. OBJECTIVE The present study investigated the long-term evolution of BPSD over one year after CBU discharge. METHODS The EVITAL cohort included 221 participants admitted to the CBUs of 3 French hospitals. BPSD were collected using the Neuropsychiatric Inventory (NPI) at admission and 3, 6, and 12 months after hospitalization. The global NPI score evolution was assessed using a linear mixed-effect model. A four-factor model of the NPI including behavioral dyscontrol, psychosis, mood, and agitation subscores was also analyzed. RESULTS Our analysis focused on 148 patients followed up during 12 months and evaluated at each visit. The global NPI score was 48.5 (SD 21.7) at baseline, 28.8 (SD 18.7) at 3-month, 23.2 (SD 16.4) at 6-month and 20.9 (SD 15.9) at 12-month follow-up. The score significantly decreased from baseline to follow-up (F = 109.3 p
Published: 2017

14. Immediate Benefit of Art on Pain and Well-Being in Community-Dwelling Patients with Mild Alzheimer's

Author: Pierre Krolak-Salmon, Béatrice Trombert, Jean-Claude Getenet, Nicolas Auguste, Romain Bachelet, Bernard Laurent, Floriane Delphin-Combe, Jean-Michel Dorey, Barbara Tillmann, Elodie Pongan, Isabelle Rouch, Yohana Lévêque, Centre Mémoire de Ressources et de Recherche (CMRR Lyon), Hospices Civils de Lyon (HCL)-Hôpital des Charpennes [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Laboratoire Parole et Langage (LPL), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Etude de l'Apprentissage et du Développement [Dijon] (LEAD), Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Service de Santé Publique et d'Information Médicale, Psychiatrie, Centre Hospitalier le Vinatier [Bron], Centre Mémoire de Ressources et de Recherche [CHU de Saint-Etienne] (CMRR 42), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)-Université Jean Monnet - Saint-Étienne (UJM), Hôpital des Charpennes [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre National de la Recherche Scientifique (CNRS)-Université de Bourgogne (UB), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), CHU Saint-Etienne, Centre Mémoire de Ressources et de Recherche [CHU de Saint-Etienne Hôpital Nord], and CHU de Saint-Étienne Hôpital Nord [Saint Etienne]
Subjects: Gerontology, Male, Pain, 03 medical and health sciences, 0302 clinical medicine, Quality of life (healthcare), Alzheimer Disease, Intervention (counseling), medicine, Humans, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Aged, Aged, 80 and over, Painting, business.industry, General Neuroscience, medicine.disease, humanities, Psychiatry and Mental health, Clinical Psychology, Well-being, Quality of Life, Female, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Independent Living, Geriatrics and Gerontology, Alzheimer's disease, Singing, business, 030217 neurology & neurosurgery, Independent living, Art, Music
Abstract: Objective: The present report aims to evaluate whether singing intervention can bring an immediate benefit that is greater than the one provided by painting intervention on pain and well-being. Methods: Fifty-nine mild patients with Alzheimer disease were randomized to a 12-week singing (n = 31) or painting group (n = 28). In the present analysis, the immediate evolution of pain and well-being was compared across sessions between the 2 groups using mixed-effects models. Results: We observed a significant improvement in well-being for both singing and painting groups immediately after sessions, compared to the assessment before the sessions. We did not observe this improvement across the sessions for pain intensity measurement. Discussion: Our results revealed that both painting and singing interventions provide an immediate benefit on the patients’ well-being.
Published: 2019

15. Determination of Adherence Profiles in Schizophrenia Using Self-Reported Adherence

Author: Caroline Dubertret, Franck Schürhoff, Joel Swendsen, Delphine Capdevielle, Marie de Pradier, Jean-Michel Dorey, F. Gabayet, Romain Rey, A. Schandrin, Jean-Marie Danion, Mathieu Urbach, Anne Marie Tronche, Christine Passerieux, Lore Brunel, Pierre-Michel Llorca, David Misdrahi, Raphaëlle Richieri, Arnaud Tessier, Isabelle Chereau, Guillaume Fond, Catherine Faget, Julien Dubreucq, and Fabrice Berna
Subjects: Adult, Male, Psychometrics, Population, Medication adherence, Comorbidity, Medication Adherence, 03 medical and health sciences, 0302 clinical medicine, Rating scale, Surveys and Questionnaires, Intervention (counseling), Humans, Medicine, In patient, education, Depression (differential diagnoses), education.field_of_study, Depression, business.industry, Electronic medical record, Reproducibility of Results, Middle Aged, medicine.disease, 3. Good health, 030227 psychiatry, Psychiatry and Mental health, Schizophrenia, Female, Self Report, business, 030217 neurology & neurosurgery, Clinical psychology
Abstract: OBJECTIVE: Medication nonadherence is one of the most important, and potentially modifiable, prognostic factors in the outcome of patients with schizophrenia. The aim of this article is to propose a new classification of adherence profiles according to the Medication Adherence Rating Scale (MARS) in a large community-dwelling sample of French patients with schizophrenia to provide a new tool to help clinicians in daily practice. METHODS: 319 community-dwelling patients from a national network of 10 Schizophrenia Expert Centers were interviewed between January 2009 and January 2014. Assessments were conducted with a dedicated electronic medical record including the Structured Clinical Interview for DSM-IV Disorders. A cluster analysis was performed to explore clinical variables associated with poor adherence. RESULTS: Two distinct groups of patients were identified relative to their main adherence style. Items about medications' subjective negative effects constituted the greatest discriminating factor between the 2 clusters. Patients with poor adherence (n = 117) were significantly younger (adjusted OR [aOR] = 1.036; 95% CI, 1.004-1.069) and had higher levels of current depression (aOR = 0.894; 95% CI, 0.829-0.964) and lower insight (aOR = 0.820; 95% CI, 0.693-0.970). CONCLUSIONS: The MARS provides a useful tool for clinicians and can also aid in the evaluation of adherence styles and their determinants in patients with schizophrenia. The element providing the greatest discriminative power between the 2 clusters was a subjective negative attitude toward medication. The findings also suggest that depression is more frequent in schizophrenia patients with poor adherence and that improving insight into illness might be suggested as a first-line intervention to improve adherence in this population.
Published: 2016

16. P1‐341: BRAIN VOLUME PREDICTS BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN ALZHEIMER'S DISEASE

Author: Catherine Padovan, Pierre Krolak Salmon, Olivier Moreaud, Philippe Robert, Denis Federico, Romain Bouet, Isabelle Gallice, Marie-Odile Barrellon, Jean-Michel Dorey, Nawele Boublay, and Zaza Makaroff
Subjects: Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, business.industry, Health Policy, Brain size, Medicine, Neurology (clinical), Disease, Geriatrics and Gerontology, business, Neuroscience
Published: 2018

17. P1‐346: REGIONAL FRONTAL CORTEX VOLUME PREDICTS APATHY IN ALZHEIMER'S DISEASE

Author: Philippe Robert, Pierre Krolak Salmon, Denis Federico, Zaza Makaroff, Catherine Padovan, Romain Bouet, Jean-Michel Dorey, Marie-Odile Barrellon, Isabelle Gallice, Olivier Moreaud, Isabelle Rouch, and Nawele Boublay
Subjects: medicine.medical_specialty, Frontal cortex, Epidemiology, business.industry, Health Policy, Disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Internal medicine, medicine, Cardiology, Apathy, Neurology (clinical), Geriatrics and Gerontology, medicine.symptom, business, Volume (compression)
Published: 2018

18. Personality Modulates the Efficacy of Art Intervention on Chronic Pain in a Population of Patients with Alzheimer's Disease

Author: Isabelle Rouch, Yohana Lévêque, Bernard Laurent, Nicolas Auguste, Barbara Tillmann, Pierre Krolak-Salmon, Jean Claude Getenet, Elodie Pongan, Béatrice Trombert, Jean-Michel Dorey, Centre Mémoire de Ressources et de Recherche [CHU de Saint-Etienne] (CMRR 42), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)-Université Jean Monnet - Saint-Étienne (UJM), Laboratoire Parole et Langage (LPL), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Etude de l'Apprentissage et du Développement [Dijon] (LEAD), Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS), Service de Santé Publique et d'Information Médicale, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Psychiatrie, Centre Hospitalier le Vinatier [Bron], Centre Mémoire de Ressources et de Recherche [CHU de Saint-Etienne Hôpital Nord], CHU de Saint-Étienne Hôpital Nord [Saint Etienne], Centre National de la Recherche Scientifique (CNRS)-Université de Bourgogne (UB), CHU Saint-Etienne, and Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne)
Subjects: Male, medicine.medical_specialty, medicine.medical_treatment, media_common.quotation_subject, [SDV]Life Sciences [q-bio], Population, law.invention, Group psychotherapy, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Alzheimer Disease, Medicine, Personality, Humans, 030212 general & internal medicine, Big Five personality traits, Brief Pain Inventory, education, ComputingMilieux_MISCELLANEOUS, media_common, Aged, education.field_of_study, business.industry, General Neuroscience, Chronic pain, Art Therapy, General Medicine, medicine.disease, Neuroticism, humanities, 3. Good health, Psychiatry and Mental health, Clinical Psychology, Physical therapy, Psychotherapy, Group, Female, Geriatrics and Gerontology, Chronic Pain, business, 030217 neurology & neurosurgery
Abstract: Background Alzheimer's disease (AD) mainly occurs in elderly individuals. Comorbidities and chronic pain are frequent in this population. Previous studies revealed that personality modulates both chronic pain (CP) andADoccurrence and evolution. Moreover, as pain treatments can induce side-effects, non-drugs treatments, such as art interventions, are interesting alternative therapies for decreasing CP in these patients. Objective Our aim was to assess the potential role of personality traits on art intervention efficacy for reducing CP in a population of patients with mild AD. Methods Design: multicenter randomized controlled trial. Fifty mild AD patients underwent a 12-week art intervention including singing and painting groups. Personality was assessed with the Big Five Inventory before the sessions. CP was measured with Numeric Rating Scale (NRS) [Usual pain (NRS-U) and most Intense pain (NRS-I)], Simple Visual Scale [Usual pain (SVS-U) and most Intense pain (SVS-I)] and Brief Pain Inventory (BPI) before and after the sessions. The influence of personality traits on CP evolution before and after art intervention was assessed with multiple linear regression models. Results A positive association was observed between neuroticism and the evolution of three CP measures including NRS-U (B = 0.34, p = 0.01), SVS-U (B = 0.20, p = 0.04), and BPI-U (B = 0.46, p = 0.02) evolution. No significant relationship was observed between neuroticism and NRS-I, SVS-I and BPI-R evolution. Conclusions Our findings suggest that neuroticism can decrease the efficacy of group art intervention on pain in patients with mild AD. Individual therapies could be more appropriate for these patients. These results emphasize the interest of taking into account patients' personality before proposing them to participate to a group therapy.
Published: 2018

19. Behavioral and psychological symptoms in Lewy body disease: a review

Author: Sophie Brunet, Mathilde Bonze, Mathieu Herrmann, Lucie Jurek, Jean-Michel Dorey, and Catherine Padovan
Subjects: Lewy Body Disease, Sleep Wake Disorders, medicine.medical_specialty, Hallucinations, medicine.medical_treatment, Disease, REM sleep behavior disorder, Diagnosis, Differential, medicine, Humans, Psychiatry, Antipsychotic, Biological Psychiatry, Aged, Aged, 80 and over, Dementia with Lewy bodies, business.industry, Parkinsonism, Cognition, medicine.disease, Affect, Neuropsychology and Physiological Psychology, Anxiety, Neurology (clinical), Geriatrics and Gerontology, medicine.symptom, Differential diagnosis, business
Abstract: Dementia with Lewy bodies (DLB) is a common neurodegenerative disease, second in terms of prevalence after Alzheimer's disease (AD). DLB may be suspected according to three core features which are cognitive and motor fluctuations, early visual hallucinations and parkinsonism; and more recently, according to the new criteria, REM sleep behavior disorder (RBD). Behavorial and psychological symptoms associated with DLB are more frequent, more severe and appear earlier than those found in other neurodegenerative diseases. They may be at the forefront and are a major diagnostic and therapeutic challenge. An improved knowledge of the pathophysiology and phenomenology associated to these symptoms can facilitate their identification as well as eliminating differential diagnoses. Managing these symptoms may require drugs when hallucinations are overwhelming and induce behavorial disorders. However, psychotropic medications are not well tolerated in this specific population and some antipsychotic drugs cannot be prescribed due to their side effects. Although further studies are needed on this subject, non-interventional treatments such as therapeutic strategies based on the patients and their caregivers appear to be essential. This paper offers a review which aims to help clinicians to identify behavioral and psychological symptoms in DLB and treat them in their daily practice.
Published: 2018

20. Factors associated with direct health care costs in schizophrenia: Results from the FACE-SZ French dataset

Author: Guillaume Fond, Marion Leboyer, Catherine Faget, Mathieu Urbach, Karine Chevreul, Romain Rey, C. Lançon, Pierre Vidailhet, F. Schürhoff, Jean-Michel Dorey, David Misdrahi, I. Chereau-Boudet, Delphine Capdevielle, Bruno Aouizerate, Sylvain Leigner, Julien Dubreucq, Myrtille André, Jasmina Mallet, Paul Roux, Pierre-Michel Llorca, Caroline Dubertret, Fabrice Berna, Amélie Prigent, Alice Plas, Charles Laidi, Service NEUROSPIN (NEUROSPIN), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Fondation FondaMental [Créteil], Pôle de Psychiatrie [Hôpital Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital H. Mondor - A. Chenevier, Epidémiologie Clinique et Evaluation Economique Appliquées aux Populations Vulnérables (ECEVE (U1123 / UMR_S_1123)), Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital universitaire Robert-Debré [Paris]-Université Paris Diderot - Paris 7 (UPD7), Hôtel-Dieu, Département de psychiatrie adulte, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital La Colombière, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital H. Mondor - A. Chenevier, Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital universitaire Robert-Debré [Paris], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Subjects: Adult, Male, medicine.medical_specialty, Adolescent, Cross-sectional study, Cost, Schizophrenia (object-oriented programming), [SDV]Life Sciences [q-bio], Psychological intervention, Cohort Studies, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Cost of Illness, Health care, Medicine, Humans, Schizophernia, Pharmacology (medical), 030212 general & internal medicine, Cognitive rehabilitation therapy, Psychiatry, Socioeconomic status, Biological Psychiatry, health care economics and organizations, Pharmacology, business.industry, Medico-economic, Health Care Costs, Middle Aged, 030227 psychiatry, 3. Good health, Hospitalization, Psychiatry and Mental health, Cross-Sectional Studies, Neurology, Cohort, Schizophrenia, Female, Neurology (clinical), France, business, Cohort study
Abstract: International audience; INTRODUCTION: There is a lack of data on health care consumption of patients suffering from schizophrenia, as well as on the related health care costs. Factors associated with health care costs have not been widely studied, whereas knowledge on this topic would allow identifying risk factors and delineating strategies to improve patients' health and follow-up, likely to also decrease health care costs. The aim of this study was to estimate the average direct health care cost of patients with schizophrenia in France and to identify the factors associated with this cost. METHODS: The study population included patients with schizophrenia enrolled in the FondaMental Advanced Centers of Expertise for Schizophrenia cohort. We accounted for the costs directly related to the treatment of schizophrenia. They included the costs of hospitalizations (full- and part-time), psychiatric ambulatory consultations and medications. We studied three categories of factors potentially associated with direct health care costs: demographic, socioeconomic and clinical characteristics. RESULTS: Three hundred and ninety five patients with schizophrenia were included. The mean (median) annual direct health care cost per patient amounted to \texteuro14,995 (\texteuro3,435). A lower level of functioning and being single were associated with a higher cost. A significant association between the expert center of inclusion and the direct health care cost of schizophrenia was also highlighted. CONCLUSION: Our results highlighted the significant cost of schizophrenia and suggest that improvement in patient care, based on well-validated targeted therapeutic interventions such as psycho-education and cognitive rehabilitation, could reduce worsening in symptom severity and therefore decrease health care costs.
Published: 2018

21. Late-life atypical reactivation of obsessive-compulsive disorder associated with frontotemporal dementia

Author: Clément Dondé, Jean-Michel Dorey, M Herrmann, and A Lepetit
Subjects: medicine.medical_specialty, Neurology, business.industry, Obsessive compulsive, Medicine, Neurology (clinical), business, medicine.disease, Psychiatry, Frontotemporal dementia
Published: 2019

22. Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia: The FACE-SZ Cohort

Author: David Misdrahi, Sylvain Leignier, Fabrice Berna, Laurent Boyer, Guillaume Fond, M. Andrianarisoa, Myrtille André, Romain Rey, Ophélia Godin, Bruno Aouizerate, Julien Dubreucq, Pierre Vidailhet, F. Schürhoff, Delphine Capdevielle, Marion Leboyer, Dominique Costagliola, Christine Passerieux, Isabelle Chereau, Jean-Michel Dorey, Pierre-Michel Llorca, Caroline Dubertret, Paul Roux, Jasmina Mallet, Christophe Lançon, and Catherine Faget
Subjects: Adult, Pediatrics, medicine.medical_specialty, Psychosis, Population, Severity of Illness Index, Medication Adherence, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Recurrence, Risk Factors, Severity of illness, medicine, Humans, Longitudinal Studies, education, Metabolic Syndrome, education.field_of_study, business.industry, Case-control study, Odds ratio, medicine.disease, 030227 psychiatry, 3. Good health, Psychiatry and Mental health, Logistic Models, Schizophrenia, Case-Control Studies, Cohort, France, business, 030217 neurology & neurosurgery, Diagnosis of schizophrenia, Antipsychotic Agents
Abstract: Objective Predicting relapse is a major challenge in schizophrenia from a clinical and medico-economic point of view. During recent decades, major psychiatric disorders have been found to be extensively associated with metabolic disorders, even before the illness onset, with a prevalence estimated to be 35% in this population. However, no study to date has, to our knowledge, explored the potential impact of metabolic syndrome (MetS) on relapse. Methods From 2010 to 2016, 185 patients (mean age = 32 years) with a DSM-IV-TR diagnosis of schizophrenia were included in the FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) cohort and followed up for 1 year. Multivariable logistic regression was performed to estimate the adjusted odds ratio for relapse. Results Thirty-seven percent of stabilized outpatients with schizophrenia (mean illness duration = 11 years) experienced a relapse at least once during the 1 year of follow-up. MetS strongly predicted relapse at 1 year, independently of illness severity, insight into illness, and treatment characteristics (including medication compliance). Patients with MetS at baseline had a 3 times higher risk (95% CI, 1.1-8.4) of experiencing a new episode of psychosis during the 12 months of follow-up. Conclusions Further studies should determine if reducing or preventing MetS could help to protect subjects with schizophrenia from relapse.
Published: 2017

23. Predictors of Discharge Destinations and Three-Month Evolution of Patients Initially Hospitalized in a Cognitive Behavioral Unit

Author: Isabelle Rouch, Denis Federico, Pierre Krolak-Salmon, Béatrice Trombert-Paviot, Jean-Michel Dorey, Claire Sellier, Elodie Pongan, Bernard Laurent, Florence Fabre, and Nicolas Auguste
Subjects: Male, medicine.medical_specialty, Patient Readmission, Severity of Illness Index, 03 medical and health sciences, 0302 clinical medicine, Sex Factors, Quality of life, Risk Factors, Internal medicine, medicine, Dementia, Humans, Prospective Studies, Aged, Aged, 80 and over, 030214 geriatrics, Cognitive Behavioral Therapy, Marital Status, business.industry, General Neuroscience, Institutionalization, Cognition, General Medicine, medicine.disease, Prognosis, Patient Discharge, Nursing Homes, Psychiatry and Mental health, Clinical Psychology, Caregivers, Spouse, Disease Progression, Quality of Life, Marital status, Population study, Female, Geriatrics and Gerontology, business, Nursing homes, 030217 neurology & neurosurgery
Abstract: BACKGROUND Previous studies showed that a third of patients living at home entered an institution after hospitalization in Cognitive and Behavioral Units (CBUs). OBJECTIVE The main objective of this study was to identify predictors of discharge destination for these patients. The secondary objective was to estimate whether institutionalization can have an impact on a patient's long-term prognosis. METHODS The study population was selected from the EVITAL study and included 140 participants living at home before hospitalization in CBUs. Factors favoring nursing-home admission were investigated and the impact of discharge destinations (i.e., home or nursing home) on patients' prognosis was examined. RESULTS Institutionalized patients were more likely to be women (F = 4.7; p = 0.03), with a higher dementia severity (F = 9.82; p = 0.007), often living alone (F = 19.69; p = 0.001), with a caregiver other than spouse (F = 8.93; p = 0.003), and with a higher patient quality of life (QoL) according to the caregiver (F = 11.73; p = 0.001). When using multivariate logistic linear regressions, we showed a relationship between marital status (OR = 0.19, 95% CI: 0.08-0.43, p
Published: 2017

24. From Diogenes syndrome to Asperger's syndrome?

Author: Jean-Michel Dorey, Catherine Padovan, Isabelle Rouch, Mathilde Bonze, and Mathieu Herrmann
Subjects: 03 medical and health sciences, Psychiatry and Mental health, medicine.medical_specialty, 0302 clinical medicine, S syndrome, Diogenes syndrome, business.industry, medicine, Geriatrics and Gerontology, medicine.disease, Psychiatry, business, 030227 psychiatry
Published: 2017

25. Mediation Analyses of Insight, Quality of Life, Depression, and Suicidality: Results From the FACE-SZ Cohort

Author: Raphaëlle Richieri, Jean-Michel Dorey, F. Gabayet, Delphine Capdevielle, Christine Passerieux, Bruno Aouizerate, A. Schandrin, Julien Dubreucq, Isabelle Chereau, Franck Schürhoff, Catherine Faget-Agius, Lore Brunel, Pierre Vidailhet, Jasmina Mallet, Pierre-Michel Llorca, Arnaud Tessier, Romain Rey, S. Fonteneau, Fabrice Berna, Caroline Dubertret, Paul Roux, Mathieu Urbach, and David Misdrahi
Subjects: Adult, Male, Mediation (statistics), Suicidal Ideation, Cohort Studies, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Quality of life, Risk Factors, Medicine, Humans, Risk factor, Suicidal ideation, Depression (differential diagnoses), Depressive Disorder, Models, Statistical, business.industry, Awareness, Middle Aged, medicine.disease, 030227 psychiatry, Psychiatry and Mental health, Cross-Sectional Studies, Psychotic Disorders, Schizophrenia, Cohort, Quality of Life, Female, medicine.symptom, business, 030217 neurology & neurosurgery, Clinical psychology, Cohort study
Abstract: Objective: The relationship between greater insight and increased risk of suicide in patients with schizophrenia is debated. The purpose of this study was to assess whether quality of life (QoL) and depression mediated the association between insight and suicidality. Methods: Between March 2010 and December 2015, 527 community-dwelling adults with stable schizophrenia according to DSM-IVcriteria were included in a multicenter cross-sectional study, the FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) Study. Structural equation modeling was used for mediation analyses among insight, QoL, depression, and suicidality, controlling for the global level of schizophrenic symptoms. Results: The model provided a good fit for the data ( (chi 3 2 =1.4, P = .708, Tucker-Lewis index = 1, comparative fit index =1, root mean square error of approximation =0, standardized root mean square residual =0.008) and explained 27% of the variance in suicidality. Poorer QoL and greater severity of depression mediated 68.4% of the positive association between insight and suicidality (full mediation). Poorer QoL mediated 48% of the positive effect of insight on depression (partial mediation). The severity of depression mediated 91.2% of the negative relationship between QoL and suicidality (full mediation). Conclusions: Insight appears to be an indirect risk factor for suicide in patients with schizophrenia, with the link being mediated by poorer QoL and worse underlying depression, mainly by a sequential pathway but also by a less important parallel pathway.
Published: 2017

26. Impact of vascular risk factors on clinical outcome in older patients with depression receiving electroconvulsive therapy

Author: Lucie Jurek, Jean-Michel Dorey, Filipe Galvao, and Jerome Brunelin
Subjects: Response rate (survey), medicine.medical_specialty, Framingham Risk Score, business.industry, medicine.medical_treatment, Retrospective cohort study, Disease, medicine.disease, behavioral disciplines and activities, Psychiatry and Mental health, Electroconvulsive therapy, Arts and Humanities (miscellaneous), Rating scale, Internal medicine, Diabetes mellitus, medicine, business, Depression (differential diagnoses)
Abstract: Introduction Despite electroconvulsive therapy (ECT) is a highly effective, safe, and well-tolerated antidepressant treatment option for geriatric patients, response rate highly varied across individuals. We hypothesized that, as seen with medication, vascular burden may in part explain those discrepancies. Objective The aim of this study was to compare response rates to ECT in elderly depressed patients presenting or not vascular risk factors (VRF). Method In a retrospective study, 54 elderly patients (age > 55; mean age 60.7 ± 13.6) with moderate to severe MDD (Montgomery–Asberg Depression Rating Scale MADRS score > 20) who received a course of ECT between March 2016 and May 2018 in our specialized unit were separated into 2 groups according to VRF. Patients of the VRF group (n = 21) should presented with at least 2 vascular risk factors among hypercholesterolemia, hypertension, smoking, diabetes mellitus, cardiovascular disease, and cerebral vascular accident/transient ischemic attack. Framingham score (10-year risk for developing a coronary heart disease) was calculated for each included subject. Our primary outcome was the number of responder to ECT (defined as 50% decrease of the MADRS following ECT course) observed between the two groups. As a secondary objective, we investigated the relationship between Framingham score and pre/post ECT MADRS score changes. Results There was no difference between the 2 groups regarding age, gender, cognitive functioning, depression severity, stage of treatment-resistant depression and illness duration. Elderly patients with vascular burden presented a lower rate of response to ECT (58.1%) than patients without vascular burden (86.7%; Chi2 = 5; P = 0.02). A negative correlation was found between Framingham score and pre/post ECT MADRS score changes (r = −0.39; 95% CI − 0.61–0.12; P = 0.01). Conclusion As observed with medication, elderly patient with vascular burden displayed a lower response rate to ECT than elderly patients without vascular burden. The more VRF increased, the less the antidepressant effect of ECT was observed.
Published: 2019

27. Development of the Alcohol Quality of Life Scale (AQoLS): a new patient-reported outcome measure to assess health-related quality of life in alcohol use disorder

Author: Pierre-Michel Llorca, Lynn Owens, Bruno Falissard, P. Laramée, Diane Whalley, Henri-Jean Aubin, N. Hawken, Mark Price, Lynda C. Doward, Jean-Michel Dorey, S.R. Crawford, Amandine Luquiens, Centre Hospitalier le Vinatier [Bron], Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Santé mentale et santé publique (SMSP - U1178), Université Paris-Sud - Paris 11 (UP11)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Commissariat à l'énergie atomique et aux énergies alternatives - Laboratoire d'Electronique et de Technologie de l'Information (CEA-LETI), Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux - Clermont Auvergne (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne (UCA), Laboratoire d'Electronique et des Technologies de l'Information (CEA-LETI), and Université Grenoble Alpes (UGA)-Direction de Recherche Technologique (CEA) (DRT (CEA))
Subjects: Adult, Male, Psychometrics, Health Status, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Psychological intervention, Poison control, Alcohol use disorder, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Quality of life (healthcare), Surveys and Questionnaires, Content validity, Humans, Medicine, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Aged, [SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior, business.industry, Debriefing, [SCCO.NEUR]Cognitive science/Neuroscience, Public Health, Environmental and Occupational Health, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Focus Groups, Middle Aged, medicine.disease, United Kingdom, 3. Good health, Patient Outcome Assessment, Alcoholism, Quality of Life, Female, Patient-reported outcome, France, Self Report, Medical emergency, Thematic analysis, business, 030217 neurology & neurosurgery, Clinical psychology
Abstract: The development of patient-centred approaches and of reduction in consumption strategies in alcohol use disorder requires giving a larger place to qualitative assessments that are closer to patients’ concerns and more clinically relevant than drinking outcomes and generic health-related quality of life instrument. Our purpose was to develop from patients input the Alcohol Quality of Life Scale (AQoLS), a disease-specific measure for alcohol use disorder (AUD). Concept elicitation focus groups were conducted with AUD patients in the UK and France. Thematic analysis was used to identify key areas of impact of AUD, and draft items were developed to capture these issues. The draft items underwent expert review to ensure clinical and cross-cultural applicability. Two iterative rounds of cognitive debriefing interviews were conducted with AUD patients in both countries, to assess face and content validity. From focus groups conducted with 38 AUD patients, seven areas of impact emerged, forming the basis for the AQoLS: relationships, activities, looking after self, emotional impact, control, living conditions, and sleep. An initial pool of 90 items was reduced to 50 following the review process. In cognitive interviews, the measure took less than 10 min to complete, and patients reported that items were relevant to their experience. Following Round 1 interviews (n = 16), 14 items were removed because patients felt they were unclear or uneasy to respond to, 2 were combined, 7 were revised, and 4 new items were added. The recall period of 2 weeks was changed to 4 weeks, based on patient comments. Following Round 2 interviews (n = 15), 5 items were removed and 3 were modified to produce the 34-item AQoLS. As the only de novo measure of health-related quality of life developed specifically for AUD, the AQoLS offers the potential of increased sensitivity to show the effectiveness of therapeutic interventions from the patient’s perspective.
Published: 2015

28. Personality, Alzheimer's disease and behavioural and cognitive symptoms of dementia: the PACO prospective cohort study protocol

Author: Jean-Michel Dorey, Pierre Krolak-Salmon, Catherine Padovan, Florence Dibie-Racoupeau, Marie-Anne Hénaff, Denis Federico, Bernard Laurent, Michel Benoit, Marie-Odile Barrellon, Nawele Boublay, Zaza Makaroff, Isabelle Rouch, Sandrine Harston, Dupuis, Christine, Système Nerveux Autonome - Epidémiologie, Physiologie, Ingénierie, Santé (SNA-EPIS), Université Jean Monnet - Saint-Étienne (UJM)-Centre Hospitalier Universitaire de Saint-Etienne, Unité de Gériatrie, Hôpital des Charpennes [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL)-Centre Mémoire de Ressources et de Recherche (CMRR Lyon), Unité de Neurologie, CHU Saint-Etienne-Centre Mémoire de Ressources et de Recherche (CMRR Saint-Etienne), Psychiatrie, Centre Hospitalier le Vinatier [Bron], Pôle Information Médicale Evaluation Recherche (IMER), Hospices Civils de Lyon (HCL), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Pôle de Gérontopsychiatrie, Hôpital Saint Jean de Dieu, Hôpital Xavier Arnozan - CHU de Bordeaux, Unité de Psychiatrie, Hôpital Pasteur [Nice] (CHU), Médecine Gériatrie, Centre hospitalier L'Hôpital du Gier (Saint-Chamond), The PACO study has been funded by the National French Program ofHospital Clinical Research (Programme Hospitalier de Recherche CliniqueNational 2009 and 2010), France Alzheimer, Janssen laboratory grants., The PACO Group : MO Barrellon, M Benoit, B Laurent, Z Makaroff, F Blanc, H Mollion, O Moreaud, C Padovan, X de Pétigny, P Rebaudet, S Relland, P H Robert, JM Dorey, I Roullet Solignac, O Rouaud, I Rouch, M Bonnefoy, F Sellal, C Terrat and A Vighetto., N Boublay, S Brengarth, MH Coste, B Croisile, D Federico, M Debray, F Dibie-Racoupeau, I Gallice, S Gaujard, P Grosmaitre, S Harston, MA Hénaff, P Krolak-Salmon, Système Nerveux Autonome - Epidémiologie, Physiologie, Ingénierie, Santé ( SNA-EPIS ), Université Jean Monnet [Saint-Étienne] ( UJM ) -Centre Hospitalier Universitaire de Saint-Etienne, Centre Mémoire de Ressources et de Recherche ( CMRR Lyon ) -Hôpital des Charpennes [CHU - HCL], Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), CHU Saint-Etienne-Centre Mémoire de Ressources et de Recherche ( CMRR Saint-Etienne ), Pôle Information Médicale Evaluation Recherche ( IMER ), Hospices Civils de Lyon ( HCL ), Centre de recherche en neurosciences de Lyon ( CRNL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] ( UJM ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Hôpital Pasteur [Nice] ( CHU ), Université Jean Monnet [Saint-Étienne] (UJM)-Centre Hospitalier Universitaire de Saint-Etienne, Centre de recherche en neurosciences de Lyon (CRNL), and Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Male, medicine.medical_specialty, Personality Inventory, media_common.quotation_subject, Population, [ SDV.MHEP.GEG ] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology, Neuropsychological Tests, Study Protocol, Cognition, Social cognition, Alzheimer Disease, medicine, Dementia, Personality, Humans, Behaviour, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Prospective Studies, 10. No inequality, Psychiatry, education, media_common, Aged, education.field_of_study, [SDV.MHEP.GEG] Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology, business.industry, [SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology, Retrospective cohort study, Middle Aged, medicine.disease, Magnetic Resonance Imaging, 3. Good health, Caregivers, [ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Disease Progression, Quality of Life, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Female, Geriatrics and Gerontology, Personality Assessment Inventory, Alzheimer's disease, business, Alzheimer’s disease, Cohort study, Follow-Up Studies
Abstract: Alzheimer’s disease is characterised by a loss of cognitive function and behavioural problems as set out in the term “Behavioural and Psychological Symptoms of Dementia”. These behavioural symptoms have heavy consequences for the patients and their families. A greater understanding of behavioural symptoms risk factors would allow better detection of those patients, a better understanding of crisis situations and better management of these patients. Some retrospective studies or simple observations suggested that personality could play a role in the occurrence of behavioural symptoms. Finally, performance in social cognition like facial recognition and perspective taking could be linked to certain personality traits and the subsequent risks of behavioural symptoms. We propose to clarify this through a prospective, multicentre, multidisciplinary study. Main Objective: - To assess the effect of personality and life events on the risk of developing behavioural symptoms. Secondary Objectives: - To evaluate, at the time of inclusion, the connection between personality and performance in social cognition tests; - To evaluate the correlation between performance in social cognition at inclusion and the risks of occurrence of behavioural symptoms; - To evaluate the correlation between regional cerebral atrophy, using brain Magnetic Resonance Imaging at baseline, and the risk of behavioural symptoms. Study type and Population: Prospective multicentre cohort study with 252 patients with Alzheimer’s disease at prodromal or mild dementia stage. The inclusion period will be of 18 months and the patients will be followed during 18 months. The initial evaluation will include: a clinical and neuropsychological examination, collection of behavioural symptoms data (Neuropsychiatric-Inventory scale) and their risk factors, a personality study using both a dimensional (personality traits) and categorical approach, an inventory of life events, social cognition tests and an Magnetic Resonance Imaging. Patients will be followed every 6 months (clinical examination and collection of behavioural symptoms data and risk factors) during 18 months. This study aims at better identifying the patients with Alzheimer’s disease at high risk of developing behavioural symptoms, to anticipate, detect and quickly treat these disorders and so, prevent serious consequences for the patient and his caregivers. ClincalTrials.gov: NCT01297140
Published: 2014

29. P2‐266: A high level of neuroticism in early‐stage Alzheimer's disease is associated with an increased risk of later developing behavior disorders

Author: Jean-Michel Dorey, Zaza Makaroff, Florence Dibie-Racoupeau, Olivier Moreaud, Pierre Krolak-Salmon, Marie-Anne Hennaf, Isabelle Rouch, Catherine Padovan, Philippe Robert, and Denis Federico
Subjects: medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Disease, Neuroticism, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Increased risk, Developmental Neuroscience, medicine, Neurology (clinical), Geriatrics and Gerontology, Stage (cooking), Psychiatry, business, Clinical psychology
Published: 2012

30. Homicide and Dementia in Older Adults

Author: Cosmin Mesu, Olivier Beauchet, Thierry Gallarda, Didier Le Gall, Cédric Annweiler, Jean-Bernard Garré, Stéphane Richard-Devantoy, and Jean-Michel Dorey
Subjects: Injury control, business.industry, Poison control, Human factors and ergonomics, medicine.disease, Suicide prevention, Occupational safety and health, Psychiatry and Mental health, Homicide, Injury prevention, medicine, Dementia, business, Clinical psychology
Published: 2010

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources

Refine your results

30 results on '"Jean-Michel Dorey"'

1. Comparative diagnosis interest of NfL and pNfH in CSF and plasma in a context of FTD–ALS spectrum

2. Redefining peripheral inflammation signature in schizophrenia based on the real-world FACE-SZ cohort

3. [Paradoxical reactions to benzodiazepines in the elderly]

4. Impact of Cognitive, Functional, Behavioral Disorders, and Caregiver Burden on the Risk of Nursing Home Placement

5. Le syndrome sérotoninergique : une revue actualisée de la littérature

6. Validation and refinement of the clinical staging model in a French cohort of outpatient with schizophrenia (FACE-SZ)

7. How do patients with Alzheimer's disease imagine their pain?

8. Overexpression of complement component C4 in the dorsolateral prefrontal cortex, parietal cortex, superior temporal gyrus and associative striatum of patients with schizophrenia

9. Impact of vascular risk factors on clinical outcome in elderly patients with depression receiving electroconvulsive therapy

10. Brain Volume Predicts Behavioral and Psychological Symptoms in Alzheimer’s Disease

11. Early and very early‐onset schizophrenia compared with adult‐onset schizophrenia: French FACE‐SZ database

12. Clinical guidelines for the management of depression with specific comorbid psychiatric conditions French recommendations from experts (the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental)

13. One-Year Evolution of Behavioral and Psychological Symptoms of Dementia in Patients Initially Hospitalized in Cognitive Behavioral Units: The EVITAL Prospective Cohort

14. Immediate Benefit of Art on Pain and Well-Being in Community-Dwelling Patients with Mild Alzheimer's

15. Determination of Adherence Profiles in Schizophrenia Using Self-Reported Adherence

16. P1‐341: BRAIN VOLUME PREDICTS BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN ALZHEIMER'S DISEASE

17. P1‐346: REGIONAL FRONTAL CORTEX VOLUME PREDICTS APATHY IN ALZHEIMER'S DISEASE

18. Personality Modulates the Efficacy of Art Intervention on Chronic Pain in a Population of Patients with Alzheimer's Disease

19. Behavioral and psychological symptoms in Lewy body disease: a review

20. Factors associated with direct health care costs in schizophrenia: Results from the FACE-SZ French dataset

21. Late-life atypical reactivation of obsessive-compulsive disorder associated with frontotemporal dementia

22. Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia: The FACE-SZ Cohort

23. Predictors of Discharge Destinations and Three-Month Evolution of Patients Initially Hospitalized in a Cognitive Behavioral Unit

24. From Diogenes syndrome to Asperger's syndrome?

25. Mediation Analyses of Insight, Quality of Life, Depression, and Suicidality: Results From the FACE-SZ Cohort

26. Impact of vascular risk factors on clinical outcome in older patients with depression receiving electroconvulsive therapy

27. Development of the Alcohol Quality of Life Scale (AQoLS): a new patient-reported outcome measure to assess health-related quality of life in alcohol use disorder

28. Personality, Alzheimer's disease and behavioural and cognitive symptoms of dementia: the PACO prospective cohort study protocol

29. P2‐266: A high level of neuroticism in early‐stage Alzheimer's disease is associated with an increased risk of later developing behavior disorders

30. Homicide and Dementia in Older Adults

Catalog

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

30 results on '"Jean-Michel Dorey"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources